Survodutide is an investigational GLP-1 and glucagon receptor agonist. Its obesity and liver-disease research programs ask different clinical questions.
SYNCHRONIZE-1 studied people without diabetes. SYNCHRONIZE-2, published on 1 October 2026, studied adults with obesity and type 2 diabetes over 76 weeks. Treatment-regimen and efficacy-estimand figures should not be silently interchanged.
A separate MASH program evaluates a specific liver disease and fibrosis-related outcomes. Reduced liver fat, improved fibrosis, and prevention of later clinical events are not interchangeable claims.
Trial route and frequency describe research protocols only. No approved brand, dose, or routine-care availability has been verified here. Products marketed using the molecule’s name cannot be assumed equivalent to the study product.
Regulatory status checked on 3 October 2026
United States: FDA approval has not been verified. An FDA warning letter dated 24 August 2026 identifies marketed survodutide products as unapproved. October Phase 3 publication is not approval evidence.
European Union: EU marketing authorisation has not been verified in this review. No approved EU product is asserted.
Official records and primary evidence
- FDA warning concerning unapproved peptides — FDA
- SYNCHRONIZE-1 Phase 3 paper — SYNCHRONIZE-1 investigators / NEJM
- SYNCHRONIZE-2 Phase 3 paper — SYNCHRONIZE-2 investigators / NEJM
- Survodutide October 2026 update — Boehringer Ingelheim
- Survodutide MASH Phase 3 registry summary — Boehringer Ingelheim trial portal
Route and frequency describe approved product records or clinical-trial protocols as identified above. They are not instructions to use, obtain, combine, or dose a medicine. This record is informational and has not been independently medically reviewed.